CA Patent

CA2343038A1 — A novel inhibitor of cataract formation

Assigned to Research Foundation of the State University of New York · Expires 2000-04-06 · 26y expired

What this patent protects

Methods of reducing the risk of cataract development in a mammal are provide d and include administering to the mammal an effective amount of a tetracyclin e derivative. A preferred tetracycline derivative administered according to th e methods of the present invention is 6.alpha…

USPTO Abstract

Methods of reducing the risk of cataract development in a mammal are provide d and include administering to the mammal an effective amount of a tetracyclin e derivative. A preferred tetracycline derivative administered according to th e methods of the present invention is 6.alpha.-deoxy 5-hydroxy-4- dedimethylaminotetracycline.

Drugs covered by this patent

Patent Metadata

Patent number
CA2343038A1
Jurisdiction
CA
Classification
—
Expires
2000-04-06
Drug substance claim
No
Drug product claim
No
Assignee
Research Foundation of the State University of New York
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.